Inventory

Inventory consists of the following at September 30, 2017 (in thousands):



	September 30, 2017		December 31, 2016
Raw materials	$	2,724	$	—
Work in process	273		—
Finished goods	77		—
Total inventories	$	3,074	$	—

Inventory acquired prior to receipt of the marketing approval for TYMLOS, totaling approximately $1.6 million, was expensed as research and development expense as incurred. The Company began to capitalize the costs associated with the production of TYMLOS upon receipt of FDA approval on April 28, 2017.